IDH inhibitors have been trialled in AML with higher degrees of success in mutant IDH1 and IDH2(Liu & Gong, 2019) (without cytotoxicity) and thus could represent an intriguing radiosensitising supplement to NCRT. Here, IDH2 is linked to acute myeloid leukemia.